Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast

11/5/24 9:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MBRX alert in real time by email

HOUSTON, Nov. 5, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will report its financial results for the quarter ended September 30, 2024, on Friday, November 8, 2024. Moleculin management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 AM ET on Monday, November 11, 2024.

Interested participants and investors may access the conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international) and referencing the Moleculin Biotech Conference Call. The live audio webcast will be accessible on the Events page of the Investors section of the Moleculin website, moleculin.com, and will be archived for 90 days.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company's lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The Company is initiating the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study is subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.

For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

Investor Contact:

JTC Team, LLC

Jenene Thomas

(908) 824-0775

[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculin-to-report-third-quarter-2024-financial-results-on-november-8-2024-and-host-conference-call-and-webcast-302296237.html

SOURCE Moleculin Biotech, Inc.

Get the next $MBRX alert in real time by email

Date

Price Target

Rating

Analyst

6/9/2025

$4.00

Buy

H.C. Wainwright

2/12/2025

Buy → Hold

Maxim Group

7/18/2022

$14.00

Outperform

Oppenheimer

Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast

Chat with this insight

Recent Analyst Ratings for
$MBRX

$MBRX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Foster Jonathan P. bought $20,000 worth of shares (28,986 units at $0.69), increasing direct ownership by 56% to 80,556 units (SEC Form 4)

George Robert E. bought $10,000 worth of shares (14,493 units at $0.69), increasing direct ownership by 8,678% to 14,660 units (SEC Form 4)

Klemp Walter V bought $129,999 worth of shares (188,404 units at $0.69), increasing direct ownership by 38% to 680,880 units (SEC Form 4)

$MBRX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

H.C. Wainwright resumed coverage on Moleculin Biotech with a new price target

Moleculin Biotech downgraded by Maxim Group

Oppenheimer resumed coverage on Moleculin Biotech with a new price target

$MBRX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Foster Jonathan P. converted options into 833 shares and covered exercise/tax liability with 203 shares, increasing direct ownership by 6% to 11,993 units (SEC Form 4)

CEO and President Klemp Walter V converted options into 1,667 shares and covered exercise/tax liability with 406 shares, increasing direct ownership by 2% to 58,296 units (SEC Form 4)

SEC Form 4 filed by Director Yan Joy

$MBRX
Press Releases

Fastest customizable press release news feed in the world

Moleculin Announces $5.9 Million Public Offering

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML

Moleculin Participates in Virtual Investor "What This Means" Segment

$MBRX
SEC Filings

Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

Amendment: SEC Form S-1/A filed by Moleculin Biotech Inc.

Amendment: SEC Form S-1/A filed by Moleculin Biotech Inc.

Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast

Chat with this insight

Recent Analyst Ratings for $MBRX

$MBRX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Foster Jonathan P. bought $20,000 worth of shares (28,986 units at $0.69), increasing direct ownership by 56% to 80,556 units (SEC Form 4)

George Robert E. bought $10,000 worth of shares (14,493 units at $0.69), increasing direct ownership by 8,678% to 14,660 units (SEC Form 4)

Klemp Walter V bought $129,999 worth of shares (188,404 units at $0.69), increasing direct ownership by 38% to 680,880 units (SEC Form 4)

$MBRX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

H.C. Wainwright resumed coverage on Moleculin Biotech with a new price target

Moleculin Biotech downgraded by Maxim Group

Oppenheimer resumed coverage on Moleculin Biotech with a new price target

$MBRX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Foster Jonathan P. converted options into 833 shares and covered exercise/tax liability with 203 shares, increasing direct ownership by 6% to 11,993 units (SEC Form 4)

CEO and President Klemp Walter V converted options into 1,667 shares and covered exercise/tax liability with 406 shares, increasing direct ownership by 2% to 58,296 units (SEC Form 4)

SEC Form 4 filed by Director Yan Joy

$MBRX Press Releases

Fastest customizable press release news feed in the world

Moleculin Announces $5.9 Million Public Offering

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML

Moleculin Participates in Virtual Investor "What This Means" Segment

$MBRX SEC Filings

Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

Amendment: SEC Form S-1/A filed by Moleculin Biotech Inc.

Amendment: SEC Form S-1/A filed by Moleculin Biotech Inc.

Recent Analyst Ratings for
$MBRX

$MBRX
Insider Purchases

$MBRX
Analyst Ratings

$MBRX
Insider Trading

$MBRX
Press Releases

$MBRX
SEC Filings